OncoMatch/Clinical Trials/NCT07801664
Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer
Is NCT07801664 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Androgen Deprivation Therapy (ADT) for prostate cancer.
Treatment: Androgen Deprivation Therapy (ADT) — For this study, high risk prostate cancer patients with lower risk ARTERA scores will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes. Specifically, patients enrolled in this study will undergo one of several dose-escalated forms of radiotherapy which would include SBRT with or without a brachytherapy boost.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Grade: Gleason 6, Gleason 7, Gleason 8, Gleason 9, Gleason 10 (Gleason)
Gleason score 8-10 OR; Baseline PSA >20 up to and including 40 ng/ml OR; Patients with Gleason score 6-7 remain eligible if the PSA criterion (>20 ng/mL) is met OR; MRI Radiographic stage T1-T3 disease without evidence of nodal involvement
Demographics
Prior therapy
Cannot have received: androgen deprivation therapy for prostate cancer >3 months duration
Exception: ADT ≤3 months allowed; assigned to separate stratum
Prior or concurrent androgen deprivation therapy for prostate cancer of >3 months duration. Prior pharmacologic androgen deprivation therapy (ADT) for prostate cancer is permitted under the following (2) conditions: 1) Participants meeting this criterion will be assigned to a separate stratum within each primary treatment cohort. 2) Patients remain eligible for enrollment provided they have received no more than 3 months of ADT in total, regardless of whether ADT was initiated before screening or registration.
Cannot have received: ARPI (enzalutamide, apalutamide, darolutamide, abiraterone)
Currently on any ARPis (including but not limited to: enzalutamide, apalutamide, darolutamide, or abiraterone)
Cannot have received: chemotherapy for prostate cancer
Prior treatment for prostate cancer, including history of chemotherapy or surgery for prostate cancer (except for prior [transurethral resection of prostate] TURP or greenlight [photo selective vaporization of prostate] PVP which would be allowed)
Cannot have received: surgery for prostate cancer
Exception: TURP or greenlight PVP allowed
Prior treatment for prostate cancer, including history of chemotherapy or surgery for prostate cancer (except for prior [transurethral resection of prostate] TURP or greenlight [photo selective vaporization of prostate] PVP which would be allowed)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NYU Langone Health · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07801664 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior androgen deprivation therapy for prostate cancer >3 months duration, ARPI, chemotherapy for prostate cancer disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages